Evonik Financials & ESG KPIs

As of Q2 2026 (published August 04, 2026)

Evonik Group Financials

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY	2026 Q1	2026 Q2
External Sales	14,955	18,488	15,267	15,157	3,777	3,499	3,391	3,403	14,069	3,427	3,893
Growth (%)	*23%*	*24%*	*-17%*	*-1%*	*-1%*	*-11%*	*-12%*	*-5%*	*-7%*	*-9%*	*11%*
Volumes (%)	*11%*	*-4%*	*-8%*	*4%*	*2%*	*-4%*	*-6%*	*2%*	*-2%*	*-2%*	*7%*
Prices	*12%*	*18%*	*-3%*	*-2%*	*-2%*	*-1%*	*-1%*	*-2%*	*-1%*	*-1%*	*7%*
Exchange Rates	*-2%*	*5%*	*-2%*	*-1%*	*1%*	*-3%*	*-3%*	*-5%*	*-2%*	*-5%*	*-2%*
Other (incl. M&A)	*2%*	*5%*	*-4%*	*-2%*	*-2%*	*-3%*	*-2%*	*0%*	*-2%*	*-1%*	*-1%*
Adjusted EBITDA	2,383	2,490	1,656	2,065	560	509	448	357	1,874	475	630
Margin	*15.9%*	*13.5%*	*10.8%*	*13.6%*	*14.8%*	*14.5%*	*13.2%*	*10.5%*	*13.3%*	*13.9%*	*16.2%*
EBIT	1,173	942	-243	577	299	236	-25	68	578	229	163
Adjusted EBIT	1,338	1,350	521	1,027	309	250	197	105	861	235	370
Margin	*8.9%*	*7.3%*	*3.4%*	*6.8%*	*8.2%*	*7.1%*	*5.8%*	*3.1%*	*6.1%*	*6.9%*	*9.5%*
Adjusted EPS	2.12	2.26	0.79	1.67	0.59	0.34	0.27	0.15	1.36	0.34	0.65
Free Cash Flow	950	785	801	873	195	-211	300	411	695	183	49
Cash Conversion Rate[1]	40%	32%	48%	42%					37%		
Capex (Cash outflow for investment in intangible assets, pp&e)	865	865	793	840	190	176	181	201	748	224	180
Capital employed (annual average)	14,799	16,192	15,406	14,493					14,038		
ROCE	9.0%	8.3%	3.4%	7.1%					6.1%		
Dividend	1.17 €	1.17 €	1.17 €	1.17 €					1.00 €		
Employees (continuing operations)	33,004	34,029	33,409	31,930	31,585	31,273	31,297	31,053	31,053	30,643	30,356

[1] Free cash flow conversion = FCF / adj. EBITDA

Evonik Group Environment, Social & Governance KPIs

Full set of ESG KPIs published seperately on our IR website: evonik.finance/investor-relations

	2021 FY	2022 FY	2023 FY	2024 FY	2025 FY
Strategy & Growth					
Sales share with "Next Generation Solutions"	41%	43%	43%	45%	48%
Governance & Compliance					
Training rate fighting money laundering	96%	97%	98%	99%	100%
Training rate antitrust law	83%	85%	89%	90%	91%
Training rate fighting corruption	92%	91%	86%	95%	96%
Training rate code of conduct	89%	89%	92%	96%	97%
Training rate Human Rights (new in 2024)			90%	84%	94%
Training rate Data security (new in 2025)					98%
Value Chain & Products					
Procurement volume (in € billion)	10.4	13.6	11.3	10.5	9.8
Production output (million metric tons)	9.5	8.4	7.5	7.3	6.0
Use of renewable raw materials in production	9.7%	11.1%	12.0%	9.0%	10.0%
Raw material suppliers covered by TfS assessments	69%	66%	67%	71%	86%
No. of sustainability audits (Evonik/TfS)	284	378	492	596	605
No. of sustainability assessments (Evonik/TfS)	1,345	1,545	1,296	1,309	926
R&D expenses (€ million)	464	461	443	459	418
The environment					
Scope 1 greenhouse gas emissions (thousands metric tons CO_2)	4,381[a]	4,221[a]	3890[b]	3,390	2.99
Scope 2 greenhouse gas emissions (thousands metric tons CO_2)	1,916[a]	1,757[a]	1400[b]	1,670	1.36
Scope 3 greenhouse gas emissions (million metric tons CO_2)	23.4	20.5[a]	18.9[b]	21.6	19.5
% Reduction in greenhouse gas emissions Scope 1 & 2 (million metric tons CO_2) vs base year	-43	-5[c]	-15[c]	-20	-31
Total water intake (in million m³)	462[d]	444[d]	403	431	427
Specific water intake (in m³ freshwater / metric ton production)	26.8[d]	29.5[d]	29.9	32.2	36.7
Production waste (thousand metric tons)	342[d]	335[d]	287	306	272
Specific production waste (in ton of waster per metric ton production)	0.036	0.04	0.038	0.042	0.045
Employees					
Early employee turnover	2.2%	1.9%	2.2%	1.7%	5.3%
Continuing professional development per employee (hours)	5	4	4	2	2.1
Women at level "Executives" (circle 1)	17.7%	20.3%	22.2%	21.8%	21%
Women at level "Senior management" (circle 2)	17.6%	17.1%	18.5%	19.1%	22%
Women in management (circle 3)	28.7%	29.9%	30.3%	31.4%	32%
Women in management (circles 1-3)	27.9%	29.1%	29.6%	30.7%	32%
Safety					
Occupational health performance index	5.6	5.5	5.5	5.5	5.6
Accident frequency rate (no. of accidents / working hours) [b]	0.19	0.25	0.21	0.14	0.18
Incident frequency rate (no. of accidents / working hours) [b]	0.48	0.49	0.43	0.44	0.44

a: adjusted figures corresponding to GHG Protocal Standards | b: Correction of data based on methodological improvements | c: for new target period 2021-2030 | d: data corrected for fast-close process

(for ESG KPI definitions please see separate "Definitions" page at the end of the file)

Custom Solutions

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY	2026 Q1	2026 Q2
Sales	5,357	6,568	5,608	5,737	1,427	1,367	1,340	1,359	5,492	1,334	1,422
Growth (yoy)	*19%*	*23%*	*-15%*	*2%*	*3%*	*-7%*	*-9%*	*-3%*	*-4%*	*-7%*	*4%*
Volumes	*14%*	*-3%*	*-11%*	*5%*	*2%*	*-5%*	*-8%*	*0%*	*-3%*	*-3%*	*4%*
Prices	*5%*	*13%*	*1%*	*-2%*	*0%*	*1%*	*1%*	*1%*	*1%*	*0%*	*3%*
Exchange Rates	*-1%*	*5%*	*-3%*	*-1%*	*1%*	*-3%*	*-3%*	*-5%*	*-3%*	*-6%*	*-1%*
Other (incl. M&A)	*1%*	*8%*	*-2%*	*0%*	*0%*	*0%*	*1%*	*1%*	*1%*	*2%*	*-2%*
Sales Additives	*3,588*	*4,523*	*3,747*	*3,908*	*974*	*942*	*899*	*868*	*3,683*	*920*	*999*
Volumes (%)	+	-	-	+	=	-	-	-	-	-	+
Prices (%)	+	+	=	-	=	=	=	=	=	=	+
Sales Care	*1,768*	*2,045*	*1,861*	*1,829*	*453*	*425*	*441*	*491*	*1,809*	*414*	*423*
Volumes (%)	+	=	-	=	+	-	-	+	=	-	-
Prices (%)	+	+	+	=	-	=	+	+	=	=	+
Adjusted EBITDA	1,086	1,162	852	978	256	254	215	184	909	227	271
Margin	*20.3%*	*17.7%*	*15.2%*	*17.0%*	*17.9%*	*18.6%*	*16.0%*	*13.5%*	*16.6%*	*17.0%*	*19.1%*
EBITDA yoy Additives	+	+	-	+	+	-	-	=	-	-	+
EBITDA yoy Care	+	+	-	-	+	-	-	+	+	-	+
EBIT				558	170	189	120	74	553	152	142
Adjusted EBIT				663	181	180	140	104	602	152	191
Capital expenditures				311	50	78	72	100	300	64	73
Approx. Operating FCF				600	44	112	172	314	642	40	138
Capital employed (annual average)				6,192					6,054		
ROCE				10.7%					9.9%		
Employees				9,736	9,746	9,649	9,644	-	9,529	9,805	9,774

2019-2023 figures pro-forma (unaudited)

Approx. Operating FCF provided as simplified indication only (unaudited). Calculated as adj. EBITDA, plus/minus NWC change, minus capex. Not including taxes, provisions and other items, thus not adding up to Group FCF.

For sales (volume and price) and EBITDA trends yoy (“+” or “-“ in case of >2% deviation; otherwise “=”)

EVONIK
Leading Beyond Chemistry

Advanced Technologies

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY	2026 Q1	2026 Q2
Sales	5,827	7,092	5,983	6,089	1,601	1,511	1,445	1,415	5,973	1,450	1,647
Growth (yoy)	*17%*	*22%*	*-16%*	*2%*	*6%*	*-1%*	*-6%*	*-6%*	*-2%*	*-9%*	*9%*
Volumes	*11%*	*-3%*	*-8%*	*2%*	*6%*	*1%*	*-2%*	*2%*	*2%*	*-1%*	*7%*
Prices	*8%*	*20%*	*-4%*	*0%*	*-3%*	*-1%*	*-1%*	*-3%*	*-2%*	*-1%*	*5%*
Exchange Rates	*-2%*	*5%*	*-4%*	*-1%*	*1%*	*-4%*	*-3%*	*-5%*	*-3%*	*-6%*	*-1%*
Other (incl. M&A)	*0%*	*0%*	*0%*	*1%*	*2%*	*3%*	*0%*	*0%*	*1%*	*-1%*	*-2%*
Sales Organics	*1,681*	*1,868*	*1,742*	*1,664*	*426*	*401*	*411*	*395*	*1,634*	*390*	*453*
Volumes (%)	+	-	-	+	+	-	+	+	+	=	+
Prices (%)	+	+	=	-	-	=	-	-	-	-	=
Sales Inorganics	*2,357*	*3,031*	*2,491*	*2,490*	*621*	*614*	*595*	*566*	*2,395*	*577*	*631*
Volumes (%)	+	=	-	+	=	-	-	=	=	-	+
Prices (%)	+	+	=	-	=	=	=	-	=	=	=
Sales Animal Nutrition	*1,789*	*2,193*	*1,750*	*1,935*	*554*	*496*	*439*	*454*	*1,944*	*484*	*563*
Volumes (%)	+	-	=	=	+	+	-	=	+	+	=
Prices (%)	+	+	-	+	-	-	-	-	-	-	+
Adjusted EBITDA	1,233	1,207	752	1,023	291	266	202	186	944	241	333
Margin	*21.2%*	*17.0%*	*12.6%*	*16.8%*	*18.2%*	*17.6%*	*14.0%*	*13.1%*	*15.8%*	*16.6%*	*20.2%*
EBITDA yoy Organics	+	=	-	-	+	-	-	-	-	+	+
EBITDA yoy Inorganics	+	+	-	+	-	=	-	+	-	+	-
EBITDA yoy Animal Nutrition	+	-	-	+	+	+	-	-	-	-	+
EBIT				517	183	137	65	60	445	125	214
Adjusted EBIT				565	181	150	89	71	492	129	217
Capital expenditures				367	56	82	72	132	342	60	88
Approx. Operating FCF				513	156	85	182	250	673	135	135
Capital employed (annual average)				7,018					6,907		
ROCE				8.1%					7.1%		
Employees				9,568	9,405	9,312	9,189	-	9,177	9,458	9,380

2019-2023 figures pro-forma (unaudited)

Approx. Operating FCF provided as simplified indication only (unaudited). Calculated as adj. EBITDA, plus/minus NWC change, minus capex. Not including taxes, provisions and other items, thus not adding up to Group FCF.

For sales (volume and price) and EBITDA trends yoy (“+” or “-“ in case of >2% deviation; otherwise “=”)

Infrastructure (SYNEQT + Oxeno businesses[1]) / Other

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY	2026 Q1	2026 Q2
Sales Infrastructure & Other	3,771	4,827	3,675	3,331	749	621	606	629	2,604	643	824
Sales Infrastructure				*3,146*	*708*	*584*	*574*	*583*	*2,449*	*577*	*749*
Sales Other				*185*	*41*	*37*	*32*	*46*	*155*	*66*	*75*
Adjusted EBITDA Infrastructure & Other	96	124	54	64	13	-11	31	-13	21	7	26
Adj. EBITDA Infrastructure				*275*	*61*	*38*	*54*	*59*	*213*	*47*	*100*
Adj. EBITDA Other				*-211*	*-48*	*-49*	*-23*	*-72*	*-192*	*-40*	*-74*
EBIT	-316	-641	-611	-498	-54	-90	-210	-66	-420	-48	-193
Adjusted EBIT	-228	-224	-296	-201	-53	-80	-32	-67	-233	-46	-38
Capital expenditures	292	241	189	138	27	25	29	50	130	21	28
Employees	16,116	16,504	16,184	12,626	12,434				12,347	11,380	11,202

[1] Infrastructure is comprised of two distinct businesses 1) SYNEQT = infrastructure assets in Marl and Wesseling and 2) Oxeno = C4 value chain in Marl and Antwerp

Group Income Statement

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY	2026 Q1	2026 Q2
Sales	14,955	18,488	15,267	15,157	3,777	3,499	3,391	3,403	14,069	3,427	3,893
Cost of sales	-10,925	-14,257	-12,567	-11,419	-2,769	-2,568	-2,775	-2,714	-10,825	-2,563	-2,931
Gross profit on sales	**4,030**	**4,231**	**2,700**	**3,738**	**1,008**	**931**	**616**	**689**	**3,244**	**864**	**962**
Selling expenses	-1,717	-2,035	-1,836	-1,894	-454	-434	-420	-428	-1,736	-419	-460
Research and development expenses	-464	-460	-443	-459	-106	-105	-104	-102	-418	-94	-96
General administrative expenses	-546	-554	-488	-740	-126	-125	-111	-113	-474	-114	-130
Other operating income & expenses	-138	-252	-186	-89	-25	-33	-7	13	-52	-9	-115
Result from investments recognized at equity	8	12	10	21	2	2	1	9	14	1	2
Income before financial result and income taxes, cont. ops. = EBIT	**1,173**	**942**	**-243**	**577**	**299**	**236**	**-25**	**68**	**578**	**229**	**163**
Financial Result	-88	-19	-108	-143	-29	-44	-52	-30	-156	-46	-41
Income before income taxes, continuing operations	**1,085**	**923**	**-351**	**434**	**270**	**192**	**-77**	**38**	**422**	**183**	**122**
Income taxes	-316	-369	-101	-194	-34	-68	-25	-18	-145	-54	-37
Income after taxes, continuing operations	**769**	**554**	**-452**	**240**	**236**	**124**	**-102**	**20**	**277**	**129**	**85**
Income after taxes, discontinued operations	-2	1	-	0	0	0	0	0	0	0	0
Income after taxes	**767**	**555**	**-452**	**240**	**236**	**124**	**-102**	**20**	**277**	**129**	**85**
thereof attributable to non-controlling interests	21	15	13	18	3	4	4	2	12	4	1
Shareholders of EVONIK Industries AG (net income)	**746**	**540**	**-465**	**222**	**233**	**120**	**-106**	**18**	**265**	**125**	**84**
EPS	**1.60**	**1.16**	**-1.00**	**0.48**	**0.50**	**0.26**	**-0.23**	**0.04**	**0.57**	**0.27**	**0.18**

Group Adjusted Income Statement

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY	2026 Q1	2026 Q2
Sales	**14,955**	**18,488**	**15,267**	**15,157**	**3,777**	**3,499**	**3,391**	**3,403**	**14,069**	**3,427**	**3,893**
Adjusted EBITDA	**2,383**	**2,490**	**1,656**	**2,065**	**560**	**509**	**448**	**357**	**1,874**	**475**	**630**
Adjusted depreciation and amortization	-1,045	-1,140	-1,135	-1,038	-251	-259	-251	-252	-1,013	-240	-260
Adjusted EBIT	**1,338**	**1,350**	**521**	**1,027**	**309**	**250**	**197**	**105**	**861**	**235**	**370**
Adjusted net financial result	-97	-19	-103	-143	-29	-44	-52	-37	-162	-46	-41
Adjusted D&A on intangible assets	162	169	153	144	34	32	33	32	131	32	31
Adjusted income before income taxes	**1,403**	**1,500**	**571**	**1,028**	**314**	**238**	**178**	**100**	**830**	**221**	**360**
Adjusted income taxes, continuing operations	-396	-431	-188	-233	-36	-74	-46	-28	-184	-59	-63
Adjusted income after taxes	**1,007**	**1,069**	**383**	**795**	**278**	**164**	**132**	**72**	**646**	**162**	**297**
Adjusted non-controlling interest	-21	-15	-13	-18	-3	-4	-4	-1	-12	-4	-1
Adjusted net income	**986**	**1,054**	**370**	**777**	**275**	**160**	**128**	**71**	**634**	**158**	**296**
Adjusted EPS	**2.12**	**2.26**	**0.79**	**1.67**	**0.59**	**0.34**	**0.27**	**0.15**	**1.36**	**0.34**	**0.65**

Adjustments

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY	2026 Q1	2026 Q2
Restructuring measures	-32	-121	-64	-405	-12	7	-31	-6	-42	-4	-48
Acquisitions and divestments	-29	40	-237	-34	-11	4	0	-7	-14	0	0
Other special items	-104	-327	-463	-11	13	-25	-191	-24	-227	-2	-159
= Adjustments	-165	-408	-764	-450	-10	-14	-222	-37	-283	-6	-207

Adjustment categories changed as of December 31, 2023 to avoid overlaps between categories; prior year figures restated

Group Balance Sheet

Assets

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 FY	2026 Q1	2026 Q2
Intangible assets	6,045	5,710	5,525	5,571	5,426	5,176	5,131	5,097	5,122	5,115
Property, plant and equipment	6,963	6,962	6,294	6,450	6,305	6,127	5,933	6,006	6,051	6,035
Right of use assets (capitalized leasing)	608	972	965	947	905	867	893	892	867	782
Investments recognized at equity	81	88	52	49	51	45	45	45	46	42
Trade accounts receivable						67	54	1	1	1
Financial assets	581	441	460	467	424	455	418	419	397	382
Deferred tax assets	1,755	890	642	664	629	624	659	436	430	466
Other income tax assets	16	19	20	25	24	22	22	22	22	63
Other non-financial assets	125	64	78	69	110	71	87	96	90	71
Non-current assets	**16,174**	**15,146**	**14,036**	**14,242**	**13,874**	**13,454**	**13,242**	**13,014**	**13,026**	**12,957**
Inventories	2,548	2,820	2,349	2,662	2,751	2,649	2,555	2,300	2,429	2,682
Other income tax assets	199	98	209	166	138	103	86	94	95	78
Trade accounts receivable	1,954	1,898	1,607	1,622	1,732	1,625	1,581	1,525	1,728	1,885
Other non-financial assets	382	517	373	381	440	377	363	333	378	426
Financial assets	571	610	381	216	574	467	266	220	212	197
Cash and cash equivalents	456	645	749	461	733	379	454	495	589	390
Current assets	**6,110**	**6,588**	**5,668**	**5,508**	**6,368**	**5,600**	**5,305**	**4,967**	**5,431**	**5,658**
Assets held for sale	0	76	236	0	0	0	0	0	0	0
Current assets	**6,110**	**6,664**	**5,904**	**5,508**	**6,368**	**5,600**	**5,305**	**4,967**	**5,431**	**5,658**
Total assets	**22,284**	**21,810**	**19,940**	**19,750**	**20,242**	**19,054**	**18,547**	**17,981**	**18,457**	**18,615**

Liabilities

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 FY	2026 Q1	2026 Q2
Issued capital	466	466	466	466	466	466	466	466	466	466
Reserves	8,823	10,508	8,444	8,554	8,719	8,028	7,883	7,644	7,764	7,406
Equity attributable to shareholders of Evonik Industries AG	**9,289**	**10,974**	**8,910**	**9,020**	**9,185**	**8,494**	**8,349**	**8,110**	**8,230**	**7,872**
Equity attributable to non-controlling interests	83	82	76	80	82	65	64	64	68	61
Total equity	**9,372**	**11,056**	**8,986**	**9,100**	**9,267**	**8,559**	**8,413**	**8,174**	**8,298**	**7,933**
Provisions for pensions and other post-employment benefits	3,766	1,359	1,858	1,662	1,449	1,383	1,387	1,490	1,547	1,538
Other provisions	657	542	517	734	734	651	667	591	597	632
Deferred tax liabilities	628	661	608	638	633	625	629	576	592	616
Other income tax liabilities	195	246	268	254	258	268	246	228	231	275
Financial liabilities	3,531	4,117	3,502	3,162	3,629	3,586	3,663	3,476	3,471	3,717
Other payables	143	182	153	141	97	109	95	118	122	122
Non-current liabilities	**8,920**	**7,107**	**6,906**	**6,591**	**6,800**	**6,622**	**6,687**	**6,479**	**6,560**	**6,900**
Other provisions	892	732	606	923	955	695	724	787	818	734
Other income tax liabilities	211	189	124	87	86	63	59	58	79	73
Financial liabilities	477	429	1,153	1,034	941	1,215	830	689	684	748
Trade accounts payable	2,022	1,735	1,521	1,600	1,702	1,440	1,359	1,401	1,521	1,738
Other payables	390	501	457	415	491	460	475	393	497	489
Current liabilities	**3,992**	**3,586**	**3,861**	**4,059**	**4,175**	**3,873**	**3,447**	**3,328**	**3,599**	**3,782**
Liabilities associated with assets held for sale	0	61	187	0	0	0	0	0	0	0
Current liabilities	**3,992**	**3,647**	**4,048**	**4,059**	**4,175**	**3,873**	**3,447**	**3,328**	**3,599**	**3,782**
Total equity and liabilities	**22,284**	**21,810**	**19,940**	**19,750**	**20,242**	**19,054**	**18,547**	**17,981**	**18,457**	**18,615**

Group Cash Flow Statement

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY	2026 Q1	2026 Q2
Income before financial result and income taxes, continuing operations = EBIT	1,173	942	-243	577	299	236	-25	68	578	229	163
Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets	1,073	1,568	1,841	1,117	240	260	428	275	1,203	239	376
Result from investments recognized at equity	-8	-12	-10	-21	-2	-3	0	-9	-14	-1	-2
Gains/losses on disposal of non current assets	43	-50	-1	22	15	4	5	-13	11	-2	7
Change in inventories	-675	-270	310	-297	-140	7	94	259	220	-104	-235
Change in trade accounts receivable	-449	42	105	21	-143	-16	52	112	5	-183	-150
Change in trade accounts payable and current advance payments received from customers	680	-257	-157	74	185	-228	-67	-32	-142	187	205
Change in provisions for pensions and other post-employment benefits	83	-19	-55	-48	-4	-13	-28	-4	-49	-8	-17
Change in other provisions	207	-149	-141	535	37	-341	40	10	-254	27	-63
Change in miscellaneous assets/liabilities	-23	10	152	-81	-100	78	7	-6	-21	46	-39
Cash inflows from dividends	19	19	25	27	0	19	0	7	26	0	18
Tax payments relating to carve-out of the methacrylates business	-	-	-	-	-	-	-	-	-	-	-
Cash inflows/outflows for income taxes	-308	-174	-232	-213	-2	-38	-25	-55	-120	-23	-34
Cash flow from operating activities, continuing operations	**1,815**	**1,650**	**1,594**	**1,713**	**385**	**-35**	**481**	**612**	**1,443**	**407**	**229**
Cash flow from operating activities, discontinued operations	0	0	0	0	0	0	0	0	0	0	0
Cash flow from operating activities	**1,815**	**1,650**	**1,594**	**1,713**	**385**	**-35**	**481**	**612**	**1,443**	**407**	**229**
Cash outflows for investments in intangible assets, property, plant and equipment, investment property	-865	-865	-793	-840	-190	-176	-181	-201	-748	-224	-180
Cash outflows for investments in shareholdings	-85	-27	-76	-15	0	0	-1	0	0	0	0
Cash outflows for loss from divestments of shareholdings	-145	97	-32	-13	0	-1	0	0	-2	0	-1
Cash outflows from divestments of businesses and other shareholdings	-21	-	-5	-6	0	0	0	0	0	0	0
Cash inflows from divestments of intangible assets, property, plant and equipment, investment property	9	5	15	21	8	0	1	12	21	10	6
Cash inflows for loss from divestments of shareholdings	2	-	43	16	3	6	0	9	18	0	0
Cash inflows for investments in shareholdings			2	0	2	1	0	10	13	4	1
Cash inflows/outflows relating to securities, deposits, loans and others	23	-3	161	137	-352	199	164	-4	8	3	9
Cash inflows from interest	12	16	32	37	18	5	6	5	38	4	4
Cash flow from investing activities, continuing operations	**-1,070**	**-777**	**-653**	**-663**	**-511**	**34**	**-11**	**-169**	**-652**	**-203**	**-161**
Cash flow from investing activities, discontinued operations	0	0	0	0	0	0	0	0	0	0	0
Cash flow from investing activities	**-1,070**	**-777**	**-653**	**-663**	**-511**	**36**	**-11**	**-169**	**-652**	**-203**	**-161**
Cash inflows/outflows relating to capital contributions	0	0	0	0	1	3	0	0	4	0	0
Cash outflows for dividends to shareholders of Evonik Industries AG	-536	-545	-545	-545	-	-545	0	0	-545	0	-466
Cash outflows for dividends to non-controlling interests	-21	-13	-10	-20	-1	-4	-4	-1	-10	-2	-3
Cash infows/outflows from changes in ownership interests in subsidiaries without loss of control	0	-5	-	0	0	-19	0	0	-19	0	0
Cash outflows for the purchase of treasury shares	-15	-16	-16	-12	0	-1	0	0	-1	0	0
Cash inflows from the sale of treasury shares	12	12	12	9	0	1	0	0	1	0	0
Cash inflows from the addition of financial liabilities	655	1,649	716	708	521	294	921	97	1,833	71	332
Cash outflows for repayment of financial liabilities	-948	-1,577	-893	-1,354	-107	-65	-1,252	-485	-1,909	-172	-110
Cash inflows/outflows in connection with financial transactions	91	-104	12	-7	2	5	0	11	16	20	6
Cash outflows for interest	-94	-73	-99	-109	-14	-10	-53	-22	-101	-29	-29
Cash flow from financing activities, continuing operations	**-856**	**-672**	**-823**	**-1,330**	**402**	**-341**	**-388**	**-400**	**-731**	**-112**	**-270**
Cash flow from financing activities, discontinued operations	0	0	0	0	0	0	0	0	0	0	
Cash flow from financing activities	**-856**	**-672**	**-823**	**-1,330**	**402**	**-341**	**-388**	**-400**	**-731**	**-112**	**-270**
Change in cash and cash equivalents	**-111**	**201**	**118**	**-280**	**276**	**-342**	**82**	**43**	**60**	**92**	**-202**
Cash and cash equivalents as of beginning of period	**563**	**456**	**645**	**749**	**461**	**735**	**379**	**454**	**461**	**495**	**589**
Change in cash and cash equivalents	-111	201	118	-280	276	-342	82	43	60	92	-202
Changes in exchange rates and other changes in cash and cash equivalents	4	-12	-14	-8	-3	-14	-7	-2	-26	2	3
Cash and cash equivalents as of end of period	**456**	**645**	**749**	**461**	**734**	**379**	**454**	**495**	**495**	**589**	**390**
Cash and cash equivalents included in assets held for sale	0	0	0	0	0	0	0	0	0	0	0
Cash and cash equivalents as on the balance sheet as of end of period	**456**	**645**	**749**	**461**	**734**	**379**	**454**	**495**	**495**	**589**	**390**

Group Net Financial Position

in € million	2021 FY	2022 FY	2023 FY	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 FY	2026 Q1	2026 Q2
Non-current financial liabilities	-3,527	-4,074	-3,320	-2,961	-3,429	-3,393	-3,482	-3,314	-3,285	-3,539
Current financial liabilitites	-232	-243	-1,006	-883	-845	-1,136	-771	-617	-562	-594
Financial debt	**-3,759**	**-4,317**	**-4,326**	**-3,844**	**-4,274**	**-4,529**	**-4,253**	**-3,931**	**-3,847**	**-4,133**
- Cash and cash equivalents	456	645	749	461	733	379	454	495	589	390
- Current securities	446	413	261	128	482	285	121	124	117	121
- Other financial assets	0	2	6	2	1	1	1	1	1	2
Financial assets	**902**	**1,060**	**1,016**	**591**	**1,216**	**665**	**576**	**620**	**707**	**513**
Net financial debt/cash as stated on the balance sheet	**-2,857**	**-3,257**	**-3,310**	**-3,253**	**-3,058**	**-3,864**	**-3,677**	**-3,311**	**-3,140**	**-3,620**
Net financial debt/cash, discontinued operations	-	-	-	0	0	0	0	0	0	0
Net financial debt/cash including discontinued operations	**-2,857**	**-3,257**	**-3,310**	**-3,253**	**-3,058**	**-3,864**	**-3,677**	**-3,311**	**-3,140**	**-3,620**

Financial KPI Definitions

Adjusted EBIT	Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets.
Adjusted EBITDA	Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors.
Adjusted net income	We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items.
Adjustments	Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business.
Free Cash Flow	The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment.
ROCE	The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period.

ESG KPI Definitions

Value added in € million	We use an impact valuation to regularly measure and analyze the direct and indirect impacts from an economic, ecological, and social perspective. This supplements our established analytical approaches. We anticipate that this will allow early identification of potential future opportunities and risks, make our business model more resilient, and improve understanding of the long-term value that our business activities create for society. We aim to assign a monetary value to individual indicators such as continuing development of employees, employment impacts, and global warming so they can be compared. Most of the factors used for this are publicly available.
Sales share with "Next Generation Solutions"	Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA) For more information please see Evonik website: Responsibility - Value Chain & Products - Sustainability Analysis
Internal Investigations	Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included.
Disciplinary Measures	Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated.
Raw Material Suppliers Covered by TfS Assessments	This number indicates how many raw material suppliers have been covered by TfS assessments in that year. The chemical industry set up the Together for Sustainability (TfS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative.
Greenhouse Gas Emissions	Scope 1: Evonik's direct energy and process-related emissions; Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach); Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, enregy requierements for offices and emissions from the disposal and recycling of products sold.
Early Employee Turnover	Turnover of newly hired employees within the first year of employment
Management circles/ levels	Management circle 1 = executive functions, i.e., top management functions in the Evonik Group Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions Management circle 3 = further management functions
Occupational Health Performance Index	This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually.
Specific water intake in m3 freshwater per metric ton production	Freshwater usage in relation to production.
Total water intake	Evonik's consumption of freshwater is the total of drinking water, groundwater, surface water, and recycled water. Total water intake is the sum of total freshwater and salt water (sea water).